Long-term safety study of HSK39004 inhaler for COPD
Part of Lungs & breathing clinical trials.
This study tests a new dry powder inhaler (HSK39004) for long-term safety in people with moderate to severe COPD. It may help if your breathing is limited despite current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You have been diagnosed with moderate to severe COPD (your breathing test shows FEV1 between 30% and 79% of normal)
- You get short of breath during daily activities (mMRC score of 2 or higher)
- You have not had a chest infection in the last 6 weeks
- You do not have a serious or unstable heart condition, cancer, or other major health problems
- You have not had lung surgery in the last year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
This study tests whether a new inhaled medication called HSK39004 is safe and effective for people with moderate to severe COPD (a lung disease that makes breathing difficult). You would use this medicine regularly over a long period and have your lung function and symptoms checked.
This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
Hear when a new Chronic Obstructive Lung Disease (COLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.